Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden cardiac death in young people and children, with an annual mortality rate of 1% ...
(RTTNews) - Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF trial, a Phase 2 clinical study to evaluate CK-586 in ...
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results